Wellington Management Group Llp Opened Huge Dexcom Inc Position

August 10, 2018 - By Jason Dias

DexCom, Inc. (NASDAQ:DXCM) LogoInvestors sentiment increased to 1.15 in Q1 2018. Its up 0.42, from 0.73 in 2017Q4. It is positive, as 32 investors sold DexCom, Inc. shares while 71 reduced holdings. 45 funds opened positions while 73 raised stakes. 98.26 million shares or 0.86% less from 99.11 million shares in 2017Q4 were reported.

Fincl Bank Of Montreal Can owns 16,373 shares or 0% of their US portfolio. Old National Bankshares In invested in 0.08% or 19,607 shares. Whittier Trust owns 0% invested in DexCom, Inc. (NASDAQ:DXCM) for 300 shares. Caprock Gp owns 3,954 shares. Amalgamated Fincl Bank invested 0.04% of its portfolio in DexCom, Inc. (NASDAQ:DXCM). Guggenheim Limited Liability Corporation has 0.01% invested in DexCom, Inc. (NASDAQ:DXCM). Shaker Invests Ltd Oh has invested 2.34% in DexCom, Inc. (NASDAQ:DXCM). Bnp Paribas Asset Mgmt Holdings Sa holds 402,406 shares. Rhumbline Advisers has invested 0.02% in DexCom, Inc. (NASDAQ:DXCM). Dimensional Fund Lp stated it has 148,342 shares. Atika Capital Mngmt Ltd Company owns 32,000 shares or 0.81% of their US portfolio. Thornburg Invest Mngmt invested 0.11% in DexCom, Inc. (NASDAQ:DXCM). Da Davidson & invested 0.01% in DexCom, Inc. (NASDAQ:DXCM). Moreover, Dafna Mgmt Lc has 2.71% invested in DexCom, Inc. (NASDAQ:DXCM) for 75,000 shares. Reynders Mcveigh Management Limited Liability, a Massachusetts-based fund reported 815 shares.

Since February 15, 2018, it had 0 insider purchases, and 22 insider sales for $24.44 million activity. On Tuesday, May 8 Leach Jacob Steven sold $1.12 million worth of DexCom, Inc. (NASDAQ:DXCM) or 13,168 shares. The insider Pacelli Steven Robert sold 3,114 shares worth $317,335. Shares for $5.47 million were sold by MOY JEFFREY on Thursday, June 28. DOUBLEDAY RICHARD sold $264,513 worth of stock or 2,581 shares. Shares for $1.42 million were sold by SAYER KEVIN R. On Monday, May 14 the insider SKYLER JAY S sold $2.64M.

The New Wellington Management Group Llp Holding in Dexcom Inc

Wellington Management Group Llp reported SC 13G/A form with the SEC for Dexcom Inc. Access it here: 000090221918000489. As reported by Wellington Management Group Llp, the filler owns 4.31% or 3,805,226 shares of the Health Care–company.

Dexcom Inc stake is new for [reportingPerson]. Date of activity: July 31, 2018. This shows Wellington Management Group Llp’s positive view for Dexcom Inc. For a institutional investor managing $826.00 billion in assets and having 1540+ experts this is interesting position.

Dexcom Inc Institutional Sentiment

Filings show 214 investors own Dexcom Inc. The ownership in Q3 2017 is very high, at Infinity of the outstanding shares. This is increased by 10530478. 98296448 were owned by these investors. 31 funds opened new Dexcom Inc stakes, 93 increased positions. There were 59 that closed positions and 69 reduced them.

Glenn W. Welling Engaged Capital Llc is an investor bullish on Dexcom Inc, owning 60000 shares as of Q3 2017 for 0.36% of its portfolio. Nathan Fischel Dafna Capital Management Llc owns 57500 shares or 1.75% of its portfolio. NY Pura Vida Investments Llc have 2.94% of its portfolio for 120000 shares. Further, Sessa Capital Im Lp reported stake worth 1.62% of its portfolio. The NY Deerfield Management Company owns 1419911 shares. Dexcom Inc is 3.13% of its portfolio.

SEC Form 13G.

Wellington Management Group Llp website.

Analysts await DexCom, Inc. (NASDAQ:DXCM) to report earnings on November, 7. They expect $-0.09 earnings per share, down 200.00 % or $0.06 from last year’s $-0.03 per share. After $-0.10 actual earnings per share reported by DexCom, Inc. for the previous quarter, Wall Street now forecasts -10.00 % EPS growth.

The stock increased 0.87% or $1.0766 during the last trading session, reaching $124.2666. About 90,629 shares traded. DexCom, Inc. (NASDAQ:DXCM) has risen 27.26% since August 10, 2017 and is uptrending. It has outperformed by 14.69% the S&P500.

DexCom, Inc., a medical device company, together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the United States and internationally. The company has market cap of $10.98 billion. The firm offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers in the hospital for the treatment of patients with and without diabetes. It currently has negative earnings. The Company’s products include DexCom G4 PLATINUM system for continuous use by adults with diabetes; DexCom G4 PLATINUM with Share, a remote monitoring system; and DexCom G5 Mobile, a CGM system that directly communicates to a patient's mobile and its data can be integrated with DexCom CLARITY, which is a next generation cloud reporting software for personalized, easy-to-understand analysis of trends to improve diabetes management.

DexCom, Inc. (NASDAQ:DXCM) Ratings Coverage

Among 15 analysts covering Dexcom (NASDAQ:DXCM), 12 have Buy rating, 1 Sell and 2 Hold. Therefore 80% are positive. Dexcom has $130 highest and $57 lowest target. $97.50’s average target is -21.54% below currents $124.2666 stock price. Dexcom had 24 analyst reports since February 12, 2018 according to SRatingsIntel. BMO Capital Markets maintained DexCom, Inc. (NASDAQ:DXCM) rating on Thursday, May 3. BMO Capital Markets has “Outperformer” rating and $86 target. Canaccord Genuity maintained DexCom, Inc. (NASDAQ:DXCM) on Wednesday, March 28 with “Buy” rating. As per Wednesday, March 28, the company rating was maintained by BMO Capital Markets. Morgan Stanley maintained the shares of DXCM in report on Friday, May 4 with “Equal-Weight” rating. As per Thursday, August 2, the company rating was maintained by Jefferies. The firm has “Equal-Weight” rating given on Friday, August 3 by Morgan Stanley. As per Wednesday, March 28, the company rating was maintained by Cowen & Co. The firm earned “Buy” rating on Thursday, August 2 by Canaccord Genuity. Piper Jaffray maintained the shares of DXCM in report on Friday, March 23 with “Buy” rating. As per Monday, February 12, the company rating was maintained by Oppenheimer.

More notable recent DexCom, Inc. (NASDAQ:DXCM) news were published by: Seekingalpha.com which released: “DexCom (DXCM) Q2 2018 Results – Earnings Call Transcript” on August 02, 2018, also Seekingalpha.com with their article: “Sonar Might Be The Future” published on July 23, 2018, Fool.com published: “Why Dexcom Is Soaring Today” on August 02, 2018. More interesting news about DexCom, Inc. (NASDAQ:DXCM) were released by: Fool.com and their article: “What DexCom Just Said About Its Future” published on August 02, 2018 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 08/02: (DXCM) (TSLA) (FTNT) Higher; (EXAS) (RRGB) (TRIP) Lower (more…)” with publication date: August 02, 2018.

DexCom, Inc. (NASDAQ:DXCM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.